Flebogamma 5% DIF
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Immune Deficiency Disease
Conditions
Primary Immune Deficiency Disease
Trial Timeline
May 1, 2008 → May 1, 2011
NCT ID
NCT00634569About Flebogamma 5% DIF
Flebogamma 5% DIF is a approved stage product being developed by Grifols for Primary Immune Deficiency Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00634569. Target conditions include Primary Immune Deficiency Disease.
What happened to similar drugs?
20 of 20 similar drugs in Primary Immune Deficiency Disease were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00634569 | Approved | Completed |
Competing Products
20 competing products in Primary Immune Deficiency Disease